119 related articles for article (PubMed ID: 30809306)
41. Doxorubicin-loaded liposomes surface engineered with the matrix metalloproteinase-2 cleavable polyethylene glycol conjugate for cancer therapy.
Askarizadeh A; Mashreghi M; Mirhadi E; Mirzavi F; Shargh VH; Badiee A; Alavizadeh SH; Arabi L; Jaafari MR
Cancer Nanotechnol; 2023; 14(1):18. PubMed ID: 36910721
[TBL] [Abstract][Full Text] [Related]
42. Screening Multidrug Resistance Reversal Agents in Traditional Chinese Medicines by Efflux Kinetics of D-Luciferin in MCF-7/DOX
Zhao Y; Tang C; Huang J; Zhang H; Shi J; Xu S; Ma L; Peng C; Liu Q; Xiong Y
ACS Omega; 2023 Feb; 8(5):4853-4861. PubMed ID: 36777569
[TBL] [Abstract][Full Text] [Related]
43. Inhibition of colorectal cancer tumorigenesis by ursolic acid and doxorubicin is mediated by targeting the Akt signaling pathway and activating the Hippo signaling pathway.
Hu D; Meng RY; Nguyen TV; Chai OH; Park BH; Lee JS; Kim SM
Mol Med Rep; 2023 Jan; 27(1):. PubMed ID: 36382656
[TBL] [Abstract][Full Text] [Related]
44. Bone morphogenetic protein 10 alleviates doxorubicin-induced cardiac injury via signal transducer and activator of transcription 3 signaling pathway.
An P; Fan D; Guo Z; Liu FY; Li CF; Yang D; Wang MY; Yang Z; Tang QZ
Bioengineered; 2022 Mar; 13(3):7471-7484. PubMed ID: 35293279
[TBL] [Abstract][Full Text] [Related]
45. Toll-like receptor 5 deficiency diminishes doxorubicin-induced acute cardiotoxicity in mice.
Ma ZG; Kong CY; Wu HM; Song P; Zhang X; Yuan YP; Deng W; Tang QZ
Theranostics; 2020; 10(24):11013-11025. PubMed ID: 33042267
[No Abstract] [Full Text] [Related]
46. Theranostic Pretargeting Drug Delivery and Imaging Platforms in Cancer Precision Medicine.
Hapuarachchige S; Artemov D
Front Oncol; 2020; 10():1131. PubMed ID: 32793481
[TBL] [Abstract][Full Text] [Related]
47. Dissolving Microneedles with Spatiotemporally controlled pulsatile release Nanosystem for Synergistic Chemo-photothermal Therapy of Melanoma.
Qin W; Quan G; Sun Y; Chen M; Yang P; Feng D; Wen T; Hu X; Pan X; Wu C
Theranostics; 2020; 10(18):8179-8196. PubMed ID: 32724465
[TBL] [Abstract][Full Text] [Related]
48. Screening for
Chakouri N; Farah C; Matecki S; Amedro P; Vincenti M; Saumet L; Vergely L; Sirvent N; Lacampagne A; Cazorla O
Theranostics; 2020; 10(18):8130-8142. PubMed ID: 32724462
[TBL] [Abstract][Full Text] [Related]
49. Alliance with EPR Effect: Combined Strategies to Improve the EPR Effect in the Tumor Microenvironment.
Park J; Choi Y; Chang H; Um W; Ryu JH; Kwon IC
Theranostics; 2019; 9(26):8073-8090. PubMed ID: 31754382
[TBL] [Abstract][Full Text] [Related]
50. Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy (Review).
Zhong YJ; Shao LH; Li Y
Int J Oncol; 2013 Feb; 42(2):373-83. PubMed ID: 23291656
[TBL] [Abstract][Full Text] [Related]
51. Doxorubicin prodrug-based nanomedicines for the treatment of cancer.
Zhao H; Yu J; Zhang R; Chen P; Jiang H; Yu W
Eur J Med Chem; 2023 Oct; 258():115612. PubMed ID: 37441851
[TBL] [Abstract][Full Text] [Related]
52. Lectin-Mediated pH-Sensitive Doxorubicin Prodrug for Pre-Targeted Chemotherapy of Colorectal Cancer with Enhanced Efficacy and Reduced Side Effects.
Yao M; Ma X; Zhang X; Shi L; Liu T; Liang X; Zhao H; Li X; Li L; Gao H; Jia B; Wang F
Theranostics; 2019; 9(3):747-760. PubMed ID: 30809306
[TBL] [Abstract][Full Text] [Related]
53. Lung cancer therapy using doxorubicin and curcumin combination: Targeted prodrug based, pH sensitive nanomedicine.
Hong Y; Che S; Hui B; Yang Y; Wang X; Zhang X; Qiang Y; Ma H
Biomed Pharmacother; 2019 Apr; 112():108614. PubMed ID: 30798129
[TBL] [Abstract][Full Text] [Related]
54. Doxorubicin/heparin composite nanoparticles for caspase-activated prodrug chemotherapy.
Khaliq NU; Sandra FC; Park DY; Lee JY; Oh KS; Kim D; Byun Y; Kim IS; Kwon IC; Kim SY; Yuk SH
Biomaterials; 2016 Sep; 101():131-42. PubMed ID: 27286189
[TBL] [Abstract][Full Text] [Related]
55. A safe, simple and efficient doxorubicin prodrug hybrid micelle for overcoming tumor multidrug resistance and targeting delivery.
Bao Y; Yin M; Hu X; Zhuang X; Sun Y; Guo Y; Tan S; Zhang Z
J Control Release; 2016 Aug; 235():182-194. PubMed ID: 27264552
[TBL] [Abstract][Full Text] [Related]
56. A pH-sensitive prodrug strategy to co-deliver DOX and TOS in TPGS nanomicelles for tumor therapy.
Xiong S; Wang Z; Liu J; Deng X; Xiong R; Cao X; Xie Z; Lei X; Chen Y; Tang G
Colloids Surf B Biointerfaces; 2019 Jan; 173():346-355. PubMed ID: 30316081
[TBL] [Abstract][Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
